CONCORDBIO Stock Overview
A biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
CONCORDBIO passed our risk checks.
Concord Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,991.20 |
| 52 Week High | ₹2,664.00 |
| 52 Week Low | ₹1,221.00 |
| Beta | 0 |
| 11 Month Change | 8.27% |
| 3 Month Change | 21.14% |
| 1 Year Change | 55.97% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 111.20% |
Recent News & Updates
Recent updates
Concord Biotech Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 14
Do Concord Biotech's (NSE:CONCORDBIO) Earnings Warrant Your Attention?
Sep 15Concord Biotech Limited (NSE:CONCORDBIO) Not Lagging Market On Growth Or Pricing
Jul 23Is Concord Biotech (NSE:CONCORDBIO) Using Too Much Debt?
Feb 14Shareholder Returns
| CONCORDBIO | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 4.9% | -0.2% | 0.3% |
| 1Y | 56.0% | 40.5% | 27.3% |
Return vs Industry: CONCORDBIO exceeded the Indian Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: CONCORDBIO exceeded the Indian Market which returned 27.3% over the past year.
Price Volatility
| CONCORDBIO volatility | |
|---|---|
| CONCORDBIO Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: CONCORDBIO has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: CONCORDBIO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,377 | Sudhir Vaid | www.concordbiotech.com |
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications.
Concord Biotech Limited Fundamentals Summary
| CONCORDBIO fundamental statistics | |
|---|---|
| Market cap | ₹198.86b |
| Earnings (TTM) | ₹3.28b |
| Revenue (TTM) | ₹10.86b |
63.5x
P/E Ratio19.2x
P/S RatioIs CONCORDBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CONCORDBIO income statement (TTM) | |
|---|---|
| Revenue | ₹10.86b |
| Cost of Revenue | ₹2.76b |
| Gross Profit | ₹8.10b |
| Other Expenses | ₹4.82b |
| Earnings | ₹3.28b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 31.35 |
| Gross Margin | 74.57% |
| Net Profit Margin | 30.20% |
| Debt/Equity Ratio | 0% |
How did CONCORDBIO perform over the long term?
See historical performance and comparison